Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: A randomized, double-blind, placebo-controlled pilot study

Journal of Vascular Access

Volumn 15, Issue 2, 2014, Pages 88-94

  Wasse, Haimanot ^a   Huang, Rong ^a   Long, Qi ^b   Zhao, Yize ^b   Singapuri, Salman ^a   McKinnon, William ^c   Skardasis, George ^c   Tangpricha, Vin ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

AVF; Dialysis access; ESRD; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; COLECALCIFEROL; PLACEBO; 1,25-DIHYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; ARTERIOVENOUS FISTULA; ARTERIOVENOUS GRAFT; ARTICLE; BLOOD VESSEL GRAFT; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; AGED; ANALOGS AND DERIVATIVES; ARTERIOVENOUS SHUNT; BLOOD; DIET SUPPLEMENTATION; GEORGIA; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ARTERIOVENOUS SHUNT, SURGICAL; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GEORGIA; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; PILOT PROJECTS; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D;

EID: 84901049467     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.5301/jva.5000187     Document Type: Article

References (48)

1. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract. 2007;105(3): c132-c138.
2. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004-1013.
3. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86(2):888-894.
4. Adorini L, Amuchastegui S, Daniel KC. Prevention of chronic allograft rejection by vitamin D receptor agonists. Immunol Lett. 2005;100(1):34-41.
5. Kobayashi H, Asano K, Kanai K, Suzaki H. Suppressive activity of vitamin D3 on matrix metalloproteinase production from cholesteatoma keratinocytes in vitro. Mediators Inflamm. 2005;2005(4):210-215.
6. Timms PM, Mannan N, Hitman GA, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95(12):787-796.
7. Wu-Wong JR, Nakane M, Ma J. Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells. Thromb Res. 2006; 118(6):709-714.
8. Ruth Wu-Wong J, Nakane M, Ma J, Cook AL. Vitamin D analogs down-regulate plasminogen activator inhibitor-1 in human coronary artery smooth muscle cells. J Thromb Haemost. 2005;3(7):1545-1546.
9. Gouni-Berthold I, Krone W, Berthold HK. Vitamin D and cardiovascular disease. Curr Vasc Pharmacol. 2009;7(3): 414-422.
10. Mitsuhashi T, Morris RC Jr, Ives HE. 1,25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest. 1991;87(6):1889-1895.
11. Somjen D, Weisman Y, Kohen F, et al. 25-Hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005; 111(13):1666-1671.
12. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008;25(3):320-325.
13. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49(5):1063-1069.
14. Alvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2012;96(3):672-679.
15. Melamed ML, Muntner P, Michos ED, et al. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol. 2008;28(6):1179-1185.
16. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Körfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41(1):105-112.
17. Carthy EP, Yamashita W, Hsu A, Ooi BS. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension. 1989;13(6 Pt 2):954-959.
18. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE. Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis. 2006;186(1):20-28.
19. Dean DD, Boyan BD, Schwartz Z, et al. Effect of 1alpha, 25-dihydroxyvitamin D3 and 24R, 25-dihydroxyvitamin D3 on metalloproteinase activity and cell maturation in growth plate cartilage in vivo. Endocrine. 2001;14(3):311-323.
20. Chen SLC, Gardner DG. Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity. J Steroid Biochem Mol Biol. 2010;118(3):135-141.
21. Wu-Wong JR, Nakane M, Ma J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res. 2007;44(1):11-18.
22. Lin R, White JH. The pleiotropic actions of vitamin D. Bioessays. 2004;26(1):21-28.
23. Lin AM, Chen KB, Chao PL. Antioxidative effect of vitamin D3 on zinc-induced oxidative stress in CNS. Ann N Y Acad Sci. 2005;1053(1):319-329.
24. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754-759.
25. Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001;37(5):970-980.
26. Misra S, Fu AA, Rajan DK, et al. Expression of hypoxia inducible factor-1 alpha, macrophage migration inhibition factor, matrix metalloproteinase-2 and-9, and their inhibitors in hemodialysis grafts and arteriovenous fistulas. J Vasc Interv Radiol. 2008;19(2 Pt 1):252-259.
27. Misra S, Lee N, Fu AA, et al. Increased expression of a disintegrin and metalloproteinase thrombospondin 1 in thrombosed hemodialysis grafts. J Vasc Interv Radiol. 2008; 19(1):111-119.
28. Wasse H, Huang R, Long Q, Singapuri S, Raggi P, Tangpricha V. Efficacy and safety of a short course of veryhigh-dose cholecalciferol in hemodialysis. Am J Clin Nutr. 2012;95(2):522-528.
29. Clinical Practice Guidelines for Vascular Access. Am J Kidney Dis. 2006;48(S):176-273.
30. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930.
31. Zehnder D, Bland R, Chana RS, et al. Synthesis of 1, 25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002;13(3):621-629.
32. Gupta GK, Agrawal T, Del Core MG, Hunter WJ III, Agrawal DK. Decreased expression of vitamin D receptors in neointimal lesions following coronary artery angioplasty in atherosclerotic swine. PLoS ONE. 2012;7(8):e42789.
33. Wasse H, Huang R, Naqvi N, Smith E, Wang D, Husain A. Inflammation, oxidation and venous neointimal hyperplasia precede vascular injury from AVF creation in CKD patients. J Vasc Access. 2012;13(2):168-174.
34. Lee T, Chauhan V, Krishnamoorthy M, et al. Severe venous neointimal hyperplasia prior to dialysis access surgery. Nephrol Dial Transplant. 2011;26(7):2264-2270.
35. Alvarez J, Wasse H, Tangpricha V. Vitamin D supplementation in pre-dialysis chronic kidney disease: a systematic review. Dermatoendocrinol. 2012;4(2):118-127.
36. Lee T, Tindni A, Roy-Chaudhury P. Improved cumulative survival in fistulas requiring surgical interventions to promote fistula maturation compared with endovascular interventions. Semin Dial. 2012;(Mar):9.
37. Badero OJ, Salifu MO, Wasse H, Work J. Frequency of swing-segment stenosis in referred dialysis patients with angiographically documented lesions. Am J Kidney Dis. 2008;51(1):93-98.
38. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int. 2002;62(4):1109-1124.
39. Wong V, Ward R, Taylor J, Selvakumar S, How TV, Bakran A. Factors associated with early failure of arteriovenous fistulae for haemodialysis access. Eur J Vasc Endovasc Surg. 1996;12(2):207-213.
40. Korten E, Toonder IM, Schrama YC, Hop WC, van der Ham AC, Wittens CH. Dialysis fistulae patency and preoperative diameter ultrasound measurements. Eur J Vasc Endovasc Surg. 2007;33(4):467-471.
41. Tare M, Emmett SJ, Coleman HA, et al. Vitamin D insufficiency is associated with impaired vascular endothelial and smooth muscle function and hypertension in young rats. J Physiol. 2011;589(Pt 19):4777-4786.
42. Harris RA, Pedersen-White J, Guo DH, et al. Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. Am J Hypertens. 2011;24(5):557-562.
43. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90(3):251-262.
44. Magid R, Murphy TJ, Galis ZS. Expression of matrix metalloproteinase-9 in endothelial cells is differentially regulated by shear stress. Role of c-Myc. J Biol Chem. 2003; 278(35):32994-32999.
45. Chang CJ, Ko YS, Ko PJ, et al. Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity. Kidney Int. 2005;68(3): 1312-1319.
46. Wasse H, Cardarelli F, De Staercke C, Hooper C, Veledar E, Guessous I. 25-Hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients. BMC Nephrol. 2011;12(1):24.
47. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem. 2004;279(34):35798-35802.
48. Beer TM, Venner PM, Ryan CW, et al. High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol. 2006;135(3):392-394.